# Citations for Research Query

**Query:** # Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Ovarian High-Grade Serous Carcinoma
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** arid1a_hippo_taz_progression_model
- **Hypothesis Label:** ARID1A-Hippo-TAZ EMT and Stemness Progression Model
- **Status in KB:** EMERGING

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: arid1a_hippo_taz_progression_model
hypothesis_label: ARID1A-Hippo-TAZ EMT and Stemness Progression Model
status: EMERGING
description: 'ARID1A is the most frequently mutated subunit of the SWI/SNF chromatin remodeling complex
  across human cancers and is recurrently altered in HGSOC. ARID1A loss derepresses TAZ (the Hippo pathway
  effector), activating epithelial-mesenchymal transition and cancer-stem-cell programs that drive metastasis
  and drug resistance. This hypothesis is parallel to (not subsumed by) the HRD/PARP synthetic lethality
  model: chromatin-remodeling loss creates a transcriptional resistance state that is orthogonal to DNA-repair
  status. TAZ inhibition would block the EMT/stemness pivot in ARID1A-deficient tumors.'
evidence:
- reference: PMID:38873993
  supports: SUPPORT
  evidence_source: IN_VITRO
  snippet: ARID1A inhibits the epithelial‑mesenchymal transition (EMT) and stemness of ovarian cancer
    cells
  explanation: Xu et al. directly establish ARID1A as a tumor suppressor that restrains EMT and stemness
    in ovarian cancer cells.
- reference: PMID:38873993
  supports: SUPPORT
  evidence_source: IN_VITRO
  snippet: ARID1A exerts its inhibitory effects on ovarian cancer cells by activating the Hippo signaling
    pathway
  explanation: The Hippo pathway is the mechanistic link between ARID1A loss and TAZ-dependent EMT/stemness
    programs.
- reference: PMID:38873993
  supports: SUPPORT
  evidence_source: IN_VITRO
  snippet: TAZ inhibitors could effectively prevent initiation and metastasis of ovarian cancer cases
    where ARID1A is lost or mutated
  explanation: Provides direct therapeutic rationale for TAZ-pathway inhibition as a pivot intervention
    in ARID1A-deficient HGSOC, supporting an interactome-rebalancing framing distinct from the PARP-platinum
    synthetic-lethal axis.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.

**Provider:** asta
**Generated:** 2026-05-26T23:19:38.247847

1. Veli-Pekka Parkkinen, Christian Wallmann, Michael Wilde, B. Clarke, P. Illari et al. (2018). Gathering Evidence of Mechanisms. https://www.semanticscholar.org/paper/06480fd932fc88915a4efb4c894a5ae4ed98452d
2. C. Tung, S. Mok, Y. Tsang, Z. Zu, Huijuan Song et al. (2009). PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. https://www.semanticscholar.org/paper/120fdba92f33c126e0e86008300cb927c4350a14
3. T. Motohara, K. Masuda, M. Morotti, Yiyan Zheng, Salma El-Sahhar et al. (2018). An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene. https://www.semanticscholar.org/paper/94e8742c8e77f59c6a2648bfdf0d8a9c9c928d7b
4. Christopher G. Smith (2017). A Resident’s Perspective of Ovarian Cancer. Diagnostics. https://www.semanticscholar.org/paper/e7187ce9b848d3233d797ed025fd8984fdc4cd36
5. G. Saed, R. T. Morris, N. Fletcher (2018). New Insights into the Pathogenesis of Ovarian Cancer: Oxidative Stress. Ovarian Cancer - From Pathogenesis to Treatment. https://www.semanticscholar.org/paper/6c74938095716cbd46a218acde0b4b89bd78f7ae
6. P. Manasa, C. Sidhanth, S. Krishnapriya, S. Vasudevan, T. Ganesan (2020). Oncogenes in high grade serous adenocarcinoma of the ovary. Genes & Cancer. https://www.semanticscholar.org/paper/b574c7493627eb15cf07acdeb10faecb215a8ce2
7. W. Lim, G. Song (2013). Discovery of Prognostic Factors for Diagnosis and Treatment of Epithelial-Derived Ovarian Cancer from Laying Hens. Journal of Cancer Prevention. https://www.semanticscholar.org/paper/0a144d24755b36e68f96ca0ecad3cfd0ba8b5c4d
8. S. Labidi-Galy, E. Papp, Dorothy Hallberg, N. Niknafs, V. Adleff et al. (2017). High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications. https://www.semanticscholar.org/paper/b491df3d0b6c859c6170c9c1a949e044cc7fce0e
9. Zilin Xianyu, Cristina Correia, C. Ung, Shizhen Zhu, D. Billadeau et al. (2024). The Rise of Hypothesis-Driven Artificial Intelligence in Oncology. Cancers. https://www.semanticscholar.org/paper/f05721d59597ea5471ac85617fda99b4e73fb936
10. J. Skogen, S. Øverland (2012). The fetal origins of adult disease: a narrative review of the epidemiological literature. JRSM Short Reports. https://www.semanticscholar.org/paper/b665dc20a1f7355f7c82e370d1e1fa3a0e2a7fce
11. Christophe Gerard Lambert, L. Black (2012). Learning from our GWAS mistakes: from experimental design to scientific method. Biostatistics (Oxford, England). https://www.semanticscholar.org/paper/7c92a4bffd527e9275e5dbc57e2037bc07fa93f9
12. J. Hirst, Jennifer Crow, A. Godwin (2018). Ovarian Cancer Genetics: Subtypes and Risk Factors. Ovarian Cancer - From Pathogenesis to Treatment. https://www.semanticscholar.org/paper/0d88e28b54f6b479e215a8d323a2699987703caf
13. D. Jelovac, D. K. Armstrong (2011). Recent Progress in the Diagnosis and Treatment of Ovarian Cancer. CA: a cancer journal for clinicians. https://www.semanticscholar.org/paper/96bac6c0748ab090fe304e3578072cf81bf6998d
14. F. Langhauser, A. I. Casas, V. Dao, E. Guney, Jörg Menche et al. (2018). A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. NPJ Systems Biology and Applications. https://www.semanticscholar.org/paper/44d6cd1d0dd2993b9a9f6b17e3f9705fb04892b8
15. M. Köbel, S. Kalloger, Niki Boyd, S. McKinney, Erika Mehl et al. (2008). Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. PLoS Medicine. https://www.semanticscholar.org/paper/eb0d584d28493e3219c8618f32f90ec6d43d04db
16. A. Bugrim (2023). Identification of disease mechanisms and novel disease genes using clinical concept embeddings learned from massive amounts of biomedical data. bioRxiv. https://www.semanticscholar.org/paper/ee810c8e4db715b5333cf89bf7034bfcaf424245
17. Keren Levanon, V. Ng, H. Piao, Yi Zhang, Martin C. Chang et al. (2009). Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. https://www.semanticscholar.org/paper/a30e02ca02a8859a9ed7f4650aeae4d6b1693fcf
18. Ranjini Sankaranarayanan, D. R. Kumar, M. Altinoz, G. J. Bhat (2020). Mechanisms of Colorectal Cancer Prevention by Aspirin—A Literature Review and Perspective on the Role of COX-Dependent and -Independent Pathways. International Journal of Molecular Sciences. https://www.semanticscholar.org/paper/555d69f79f30caac17aa904dec6b811cef0733c6
